The purpose of this study is to establish the influence of the non-steroidal candidate-drug
pemirolast on allergen-induced airway obstruction and inflammation in allergic subjects with
asthma. Pemirolast is an orally available inhibitor of the release of mast cell mediators.
The study will therefore test the hypothesis that global inhibition of the mast cell,
resulting in decreased production of most of its mediator molecules, will provide a highly
significant anti-asthmatic effect.
Phase:
Phase 2
Details
Lead Sponsor:
Karolinska University Hospital
Collaborators:
Dept. Respiratory Medicine, University of Amsterdam, Amsterdam Div Clinical Pharmacology, Karolinska University Hospital Experimental Asthma and Allergy Research Unit, Karolinska Institutet Occupational and Environmental Medicine, Sahlgrenska UH, Gothenburg The Centre for Infection Medicine, Karolinska Institutet Unit for Chemistry II, Department of Medical Biochemistry, Karolinska Institutet